pazopanib + esomeprazole

**Pazopanib + esomeprazole** is a combination of two pharmaceutical drugs: - **Pazopanib** is an orally administered, small-molecule multitargeted tyrosine kinase inhibitor primarily targeting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3), platelet-derived growth factor receptor (PDGFR), and c-KIT, leading to inhibition of angiogenesis and tumor growth. Pazopanib is approved for the treatment of advanced renal cell carcinoma and soft tissue sarcoma. - **Esomeprazole** is a proton pump inhibitor (PPI) that reduces stomach acid production by irreversibly blocking H+/K+ ATPase in gastric parietal cells. It is commonly used to treat gastroesophageal reflux disease (GERD) and related acid disorders. **Combined use**: Pharmacokinetic studies and clinical data indicate that concomitant administration of esomeprazole (or any proton pump inhibitor) with pazopanib significantly decreases systemic exposure to pazopanib, reducing its maximum concentration (Cmax) and area under the curve (AUC) by approximately 40%. This results in reduced antitumor efficacy of pazopanib, as shown by lower response rates and shorter overall survival in patients with concurrent use, although some studies report non-significant effects on survival for metastatic renal cell carcinoma. The effect is considered clinically significant, and most guidelines warn against combining these drugs unless no alternatives exist[1][2][3][4].

Other names

pazopanib and esomeprazolepazopanib plus esomeprazole